Narrow search
Showing 1 - 10 of 36,491
Cover Image
Pharmacological Management of Overactive Bladder: A Systematic and Critical Review of Published Economic Evaluations
Getsios, Denis; El-Hadi, Wissam; Caro, Ingrid; Caro, J. … - In: PharmacoEconomics 23 (2005) 10, pp. 995-1006
treatments - mainly on the two most commonly used drugs, oxybutynin and tolterodine, each of which is available in immediate- and … treatment have concluded that drug therapy is cost effective. Analyses comparing the formulations of oxybutynin and tolterodine … pharmacoeconomic comparison of oxybutynin and tolterodine formulations, incorporating all available clinical data, and other treatment …
Persistent link: https://www.econbiz.de/10005590290
Cover Image
Corrigendum
Adis International Limited - In: PharmacoEconomics 30 (2012) 6, pp. 534-535
Persistent link: https://www.econbiz.de/10010548288
Cover Image
Management of Overactive Bladder: Defining the Role of Extended-Release Tolterodine
Keam, Susan J.; Perry, Caroline M. - In: Disease Management and Health Outcomes 12 (2004) 2, pp. 121-142
-release oxybutynin. The incidence of dry mouth with extended-release tolterodine or transdermal oxybutynin is similar. In economic models …-release tolterodine or immediate-release oxybutynin, and is as cost effective as extended-release oxybutynin. In conclusion, clinical and … efficacy and tolerability (including dry mouth) to transdermal oxybutynin. Extended-release tolterodine is, therefore, a …
Persistent link: https://www.econbiz.de/10005404696
Cover Image
Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease: A Review of the Evidence and Methodological Issues
Rutten-van Molken, Maureen P.M.H. Rutten-van Mlken; … - In: PharmacoEconomics 30 (2012) 4, pp. 271-302
Background:Background: Over 200 million people have chronic obstructive pulmonary disease (COPD) worldwide. The number of disease-year equivalents and deaths attributable to COPD are high. Guidelines for the pharmacological treatment of the disease recommend an individualized step-up approach in...
Persistent link: https://www.econbiz.de/10009653280
Cover Image
Urge Incontinence: Quality of Life and Patients' Valuation of Symptom Reduction
O'Conor, Richard M.; Johannesson, Magnus; Hass, Steven L.; … - In: PharmacoEconomics 14 (1998) 5, pp. 531-539
Objective: Previous studies have demonstrated the effect of incontinence, and urge incontinence in particular, on patients' quality of life. This study assessed the effects of urge incontinence on quality of life and measured the value of a reduction in symptoms. Design: A self-administered...
Persistent link: https://www.econbiz.de/10005590522
Cover Image
Disease Burden of Overactive Bladder: Quality-of-Life Data Assessed Using ICI-Recommended Instruments
Basra, Ramandeep; Kelleher, Con - In: PharmacoEconomics 25 (2007) 2, pp. 129-142
Overactive bladder (OAB) is characterised by the storage symptoms of urgency, with or without urge incontinence, and usually with urinary frequency and nocturia. OAB is a common condition that affects people of all ages within society. It has an estimated prevalence of 16% and is known to...
Persistent link: https://www.econbiz.de/10005590373
Cover Image
Establishing the Content Validity of the King's Health Questionnaire in Men and Women with Overactive Bladder in the US
Margolis, Mary Kay.; Vats, Vasudha; Coyne, Karin S.; … - In: The Patient: Patient-Centered Outcomes Research 4 (2011) 3, pp. 177-187
Background: Overactive bladder (OAB) consists of the symptoms of urinary urgency (with or without urgency incontinence) and increased urinary frequency and nocturia. As OAB is defined by symptoms, the patient is the best source of information for assessing the impact of the condition on...
Persistent link: https://www.econbiz.de/10010614417
Cover Image
Cost Effectiveness of Drug-Eluting Stents in Acute Myocardial Infarction Patients in Germany: Results from Administrative Data Using a Propensity Score-Matching Approach
Baumler, Michael Bumler; Stargardt, Tom; Schreyogg, … - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 235-248
Background:Background: The high number of patients with acute myocardial infarction (AMI) has facilitated greater research, resulting in the development of innovative medical devices. So far, results from economic evaluations that compared drug-eluting stents (DES) and bare-metal stents (BMS)...
Persistent link: https://www.econbiz.de/10011005060
Cover Image
Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension
Roman, Antonio; Barberà, Joan A. Barber; Escribano, Pilar - In: Applied Health Economics and Health Policy 10 (2012) 3, pp. 175-188
Background:Background: Pulmonary arterial hypertension (PAH) is considered an orphan disease. Prostacyclins are the keystone for PAH treatment. Choosing between the three available prostacyclin therapies could be complicated because there are no comparison studies, so the final decision must be...
Persistent link: https://www.econbiz.de/10011005061
Cover Image
Cost-Effectiveness Analysis of Early versus Non-Early Intervention in Acute Migraine Based on Evidence from the 'Act when Mild' Study
Slof, John - In: Applied Health Economics and Health Policy 10 (2012) 3, pp. 201-215
Background:Background: In spite of the important progress made in the abortive treatment of acute migraine episodes since the introduction of triptans, reduction of pain and associated symptoms is in many cases still not as effective nor as fast as would be desirable. Recent research pays more...
Persistent link: https://www.econbiz.de/10011005063